Fresenius (company)
Tracked across 1 events · 8 articles · First seen Apr 01, 2026 · Last active Sep 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for…
Impact: As majority owner of mAbxience, Fresenius gains indirect exposure to the expanded biosimilar pipeline, a modest positive for its healthcare segment.
Sep 18, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Fresenius (company) live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard